Decacorns are the new unicorns
1. Key Themes
AI Capital Concentration Is Redefining the Venture Market
The venture market is no longer broadly distributed — it is consolidating rapidly around a small number of AI bets at historic scale. "Mega-deals, or rounds of at least $100 million, accounted for 87.5% of the $412.7 billion VCs invested in startups in the first half of 2026. That total has already surpassed last year's cumulative deal value of $319.2 billion." AI is the engine: "Total deal value of investments into AI startups from January through June amounted to $355.9 billion, or 86% of all US venture investment."
Decacorns Are the New Unicorns — and 2021's Record Is Falling
The threshold for what constitutes a milestone private company has shifted dramatically upward. "Already, 19 startups have crossed the $10 billion valuation mark in 2026, eclipsing 2025's full-year tally of 18." The pace suggests 2021's record of 22 decacorns in a full year will be surpassed. "The trend reflects a broader resurgence in the venture market driven by mega-deals, especially as investors pile into AI startups insatiably."
Biopharma Exits Are Rebounding — But Durability Is Uncertain
After years of trapped LP capital, biopharma is finally delivering returns. "Total value reached a record $34.4 billion in Q2." The rebound is being driven by pharma M&A (Eli Lilly flush from GLP-1 revenues) and back-to-back record IPO debuts. However, sustainability is in question: "historically, a string of post-IPO clinical failures has slammed the window shut again."
A New Biopharma Company Formation Model Is Compressing Exit Timelines
A structural change in how biopharma companies are built is quietly reshaping deal flow. "A new model of companies, in which experienced teams form around in-licensed assets — often from China — and raise large rounds for late-stage trials, compressing exit timelines." This is refilling the backlog that powered the current rebound.
AI Speeds Up Deal Processes, But Has Not Yet Improved Investment Judgment
Wall Street is integrating AI into deal workflows, but the article draws a sharp distinction between efficiency and quality. "AI is not making investment better, yet. Wall Street is increasingly using AI to facilitate deals, but while processes are faster, humans are still needed."
2. Contrarian Perspectives
Reported VC Returns Are Likely Overstated Relative to Underlying Reality The article's Chart of the Day surfaces a meaningful divergence between what LPs are seeing and what's actually happening beneath the surface. "The VC desmoothed nowcast sits at 2.3% — a big gap from the reported-return nowcast of 5.5%. This suggests that reported returns may remain elevated in the near term, but that there's a more measured return environment beneath the surface." LPs celebrating strong reported returns in 2026 may be looking at smoothed, lagging valuations rather than true mark-to-market performance.
Biotech as an AI Bubble Hedge The conventional view is that biotech and AI are competing for capital. The contrarian framing here: biotech may be the rational hedge against AI overexposure. The article references a related story: "Some investors are turning to biotech as a hedge against potential AI bubbles." Given the concentration of AI in VC portfolios (86% of all US venture investment), diversifying into biotech is not just a sector bet — it's a portfolio risk management move.
US Tech Leaders Want Open Access to Chinese AI Models Against the prevailing geopolitical consensus favoring AI decoupling from China, major US tech CEOs are lobbying in the opposite direction. "CEOs of major tech companies signed an open letter lobbying the US government not to ban such models, including from China." This suggests industry insiders believe restricting Chinese open-weight models would harm US competitiveness more than it would protect national security.
3. Companies Identified
- Description: AI infrastructure company
- Why mentioned: Recent decacorn; used as a case study for the dynamics of AI mega-round fundraising
- Quote: "His company crossed the threshold earlier this month when it raised $1 billion in a Series F round led by General Atlantic at an $11 billion valuation."
- Description: AI-driven drug discovery company
- Why mentioned: Raised one of the largest biotech rounds in history, illustrating capital concentration in biopharma VC
- Quote: "Isomorphic Labs' $2 billion round — the second largest in biotech history — accounted for nearly 20% of the total [biopharma VC] that quarter."
Kailera Therapeutics & Parabilis Medicines
- Description: Biopharma companies
- Why mentioned: Set back-to-back record IPO debuts in Q2, driving the biopharma exit rebound
- Quote: "IPO activity also had a strong quarter, with back-to-back record-setting debuts from Kailera Therapeutics and Parabilis Medicines."
Eli Lilly
- Description: Global pharmaceutical giant
- Why mentioned: Key driver of biopharma M&A through GLP-1 windfall cash
- Quote: "Eli Lilly, most notably, was flush with cash from the GLP-1 boom."
Colossal Biosciences
- Description: Biotech / de-extinction startup
- Why mentioned: Cited as a pre-revenue decacorn raising at a $20B+ valuation, illustrating the spectrum of decacorn quality
- Quote: "Other emerging decacorns are still pre-revenue or are burning large amounts of cash for growth, such as Colossal Biosciences, which is raising new funding at a valuation north of $20 billion."
- Description: Infrastructure platform for AI agents developing software
- Why mentioned: Recent Series A; example of early-stage AI infrastructure investment
- Quote: "Fly.io, a developer of infrastructure for AI agents developing software, secured a $25 million Series A led by Dell Technologies Capital and Intel Capital."
- Description: Insurtech startup operating 24-hour coffee shops
- Why mentioned: Raised at a $4 billion valuation in a Series B extension — notable for its hybrid business model
- Quote: "Corgi, a San Francisco-based startup that provides insurance tech along with operating two 24-hour coffee shops, raised a second extension of its Series B at a $4 billion valuation."
- Description: AI image generation company
- Why mentioned: Acquiring Co-Star, signaling AI companies expanding into consumer/social verticals
- Quote: "Midjourney agreed to acquire Spark Capital-backed astrology platform developer Co-Star."
Nestlé / Platinum Equity
- Description: Nestlé is a global food and beverage conglomerate; Platinum Equity is a PE firm
- Why mentioned: Illustrates the accelerating European corporate carveout wave
- Quote: "Nestlé's $3 billion sale of half its water business to Platinum Equity is the latest sign that Europe's corporate carveout wave is building toward its second-strongest year on record."
Gravis Robotics
- Description: Zurich-based startup enhancing autonomy of earthmoving equipment
- Why mentioned: SoftBank is considering an acquisition, signaling continued appetite for physical-world robotics
- Quote: "SoftBank Group is considering an acquisition of Gravis Robotics, a Zurich-based startup that enhances the autonomy of earthmoving equipment."
Kausable
- Description: German frontier AI lab
- Why mentioned: Raised a €12M seed round — notable as a European frontier lab entering the market
- Quote: "German frontier lab Kausable raised a €12 million seed round led by UVC Partners and Entourage."
4. People Identified
Rodrigo Liang
- Description: Co-founder and CEO of SambaNova Systems
- Why mentioned: Provided on-the-record insight into the logic behind AI mega-round dynamics
- Quote: "In that condensed timeframe, what you're seeing is that, in order to deploy [capital] faster, the industry is putting its bet on fewer players that have gotten to scale."
Ben Zercher
- Description: Senior Research Analyst, Biotech & Pharma at PitchBook
- Why mentioned: Author of the biopharma exit analysis
- Quote: "LPs are finally seeing returns similar to the sector's pandemic-era heyday, but the bigger question is whether it will last."
Michael Bodley
- Description: Senior Reporter at PitchBook
- Why mentioned: Author of the decacorn analysis
- Quote: "Nineteen startups crossed the $10 billion valuation mark as AI mega-deals concentrate capital at the top."
5. Operating Insights
In-Licensing Chinese Assets Is Now a Legitimate Company Formation Strategy Founders and operators in biopharma should recognize that building a company around in-licensed assets from China — rather than internal discovery — has become an institutionally accepted path to rapid capital formation and faster exits. "A new model of companies, in which experienced teams form around in-licensed assets — often from China — and raise large rounds for late-stage trials, compressing exit timelines." For entrepreneurs in life sciences, this is a template worth studying.
Tender Offers Are Becoming a Primary Liquidity Mechanism, Reducing IPO Urgency For late-stage startup operators and employees, the secondary market is now a viable and increasingly common liquidity path that removes IPO pressure as a forcing function. "Many decacorns have been private for years, generate ample revenue and face no immediate pressure to go public, especially thanks to tender offers enabling longstanding investors and employees to cash out without an IPO."
AI Speeds Processes But Hasn't Replaced Human Judgment — Sell the Workflow Layer For operators building AI tools for financial services, the current gap is clear: AI is useful for process efficiency but not yet for decision quality. "Wall Street is increasingly using AI to facilitate deals, but while processes are faster, humans are still needed." The near-term opportunity is in workflow and due diligence automation, not autonomous decision-making.
6. Overlooked Insights
The Biopharma Backlog That Powered This Rebound Is Now Being Depleted The current exit boom is partly a catch-up phenomenon from companies that matured during the downturn — and that pipeline is not self-replenishing. "Part of this cycle's strong dealmaking comes from a backlog of high-quality companies that matured during the market downturn and are now reaping the rewards... keeping the rebound going will require getting capital back to early-stage startups that will carry the torch." Early-stage biopharma, currently underweighted, may be the highest-conviction opportunity looking 5–7 years forward.
Silicon Valley Is Quietly Defunding University AI Research Buried in the Side Letters section is a structural risk to the long-term AI talent pipeline. "Silicon Valley is leaving computer science programs without professors, poaching academics from universities across the country for roles at major AI companies." The compounding effect — fewer professors training fewer researchers — is a slow-moving but significant risk to the innovation ecosystem that AI's dominance depends on.